Lilly invests $3 billion to expand Wisconsin plant for weight-loss and diabetes drugs

Eli Lilly announced a $3 billion investment to expand its manufacturing plant in Pleasant Prairie, Wisconsin. This expansion aims to increase production of its weight-loss drug Zepbound and diabetes treatments, addressing high demand and previous shortages. The investment will boost Lilly's total commitment to the Wisconsin site to $4 billion. The company plans to start construction next year, with production expected to begin by the end of 2025. The expansion will create 750 new jobs at the facility. Lilly's weight-loss drug Zepbound has seen over 5.2 million prescriptions since its U.S. launch in late 2023. The company has invested more than $23 billion in manufacturing since 2020 to enhance its production capabilities.